The DOI matches its Crossref record; 54 of the 56 references it cites were found in a registry or an index; 13 of the 29 sources its claims cite were checked for support.
Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis
Open accessAbstract
A systematic review and random-effects model network meta-analysis were conducted to compare the efficacy, acceptability, tolerability, and safety of antidepressants to treat adults with major depressive disorder (MDD) in the maintenance phase. This study searched the PubMed, Cochrane Library, and Embase databases and included only double-blind, randomized, placebo-controlled trials with an enrichment design: patients were stabilized on the antidepressant of interest during the open-label study and then randomized to receive the same antidepressant or placebo. The outcomes were the 6-month relapse rate (primary outcome, efficacy), all-cause discontinuation (acceptability), discontinuation due to adverse events (tolerability), and the incidence of individual adverse events. The risk ratio with a 95% credible interval was calculated. The meta-analysis comprised 34 studies (n = 9384, mean age = 43.80 years, and %females = 68.10%) on 20 antidepressants (agomelatine, amitriptyline, bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, levomilnacipran, milnacipran, mirtazapine, nefazodone, paroxetine, reboxetine, sertraline, tianeptine, venlafaxine, vilazodone, and vortioxetine) and a placebo. In terms of the 6-month relapse rate, amitriptyline, citalopram, desvenlafaxine, duloxetine, fluoxetine, fluvoxamine, mirtazapine, nefazodone, paroxetine, reboxetine, sertraline, tianeptine, venlafaxine, and vortioxetine outperformed placebo. Compared to placebo, desvenlafaxine, paroxetine, sertraline, venlafaxine, and vortioxetine had lower all-cause discontinuation; however, sertraline had a higher discontinuation rate due to adverse events. Compared to placebo, venlafaxine was associated with a lower incidence of dizziness, while desvenlafaxine, sertraline, and vortioxetine were associated with a higher incidence of nausea/vomiting. In conclusion, desvenlafaxine, paroxetine, venlafaxine, and vortioxetine had reasonable efficacy, acceptability, and tolerability in the treatment of adults with stable MDD.
Overview
CoChat Summary
TL;DR
This systematic review and Bayesian network meta-analysis compared 20 antidepressants with placebo for maintenance treatment of adults with major depressive disorder, using double-blind randomized placebo-controlled trials with an enrichment design. Desvenlafaxine, paroxetine, venlafaxine, and vortioxetine had the best balance of efficacy, acceptability, and tolerability, though desvenlafaxine and vortioxetine carried a higher risk of nausea/vomiting.
Key findings
- The analysis included 34 double-blind randomized placebo-controlled trials with an enrichment design (n = 9,384; mean age = 43.80 years; 68.10% females) covering 20 antidepressants plus placebo.
- For the 6-month relapse rate, amitriptyline, citalopram, desvenlafaxine, duloxetine, fluoxetine, fluvoxamine, mirtazapine, nefazodone, paroxetine, reboxetine, sertraline, tianeptine, venlafaxine, and vortioxetine outperformed placebo, with risk ratios ranging from 0.149 (95% CrI 0.018–0.610) for nefazodone to 0.583 (95% CrI 0.410–0.789) for fluoxetine.
- Compared with placebo, desvenlafaxine, paroxetine, sertraline, venlafaxine, and vortioxetine had lower all-cause discontinuation, with risk ratios ranging from 0.523 (95% CrI 0.327–0.817) for paroxetine to 0.768 (95% CrI 0.518–0.998) for vortioxetine.
- Sertraline was associated with a higher rate of discontinuation due to adverse events; desvenlafaxine, sertraline, and vortioxetine were associated with higher nausea/vomiting, while venlafaxine was associated with lower dizziness.
Methods
- Systematic review and random-effects Bayesian network meta-analysis of double-blind, randomized, placebo-controlled trials with an enrichment design and minimum 12-week duration; patients were stabilized on the antidepressant of interest during open-label treatment and then randomized to the same antidepressant or placebo.
- Searched PubMed, Cochrane Library, and Embase; included 34 studies (n = 9,384) on 20 antidepressants and placebo. Outcomes were 6-month relapse rate (primary), all-cause discontinuation, discontinuation due to adverse events, and individual adverse events.
- Calculated risk ratios with 95% credible intervals; also performed pairwise meta-analyses, heterogeneity assessment, transitivity testing, meta-regression, ROB2 quality assessment, and CINeMA grading.
Limitations
- Stated: the number of participants and trials for some antidepressants, especially tricyclics, was small, and some results were based on only one study; the study did not cover important clinical issues such as monotherapy versus combination with nonpharmacological treatments, and did not include some side effects such as agitation due to lack of data.
- Stated: because no double-blind randomized placebo-controlled trials with an enrichment design existed for treatments such as lithium or psychotherapy, those treatments were not evaluated.
- Evident from the text: no head-to-head studies compared different antidepressants, so statistical incoherence could not be evaluated; publication bias was rated “suspected” for all comparisons because funnel plots had fewer than 10 studies; confidence in the evidence for the primary outcome was “very low” for all comparisons except vortioxetine versus placebo, which was “low”; 31 of 34 studies were industry-sponsored.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
9 Valid · 1 Not valid · 8 Not checked · 49 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Thus, when comparing the efficacy of individual antidepressants, a network meta-analysis is likely to yield more robust results than a pairwise meta-analysis.”
§ Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis > Discussion
What the sources say
- Not matchedcites [9] Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.2. wwwtrainingcochraneorg/handbook 2021.
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Supportedcites [58] Leucht S, Chaimani A, Cipriani AS, Davis JM, Furukawa TA, Salanti G. Network meta-analyses should be the highest level of evidence in treatment guidelines. Eur Arch Psychiatry Clin Neurosci. 2016;266:477–80. source
In the main text (page unavailable), the paper says network meta-analysis combines direct and indirect comparisons, increasing statistical power and precision beyond conventional pairwise meta-analysis. It also cites a network meta-analysis of antidepressants as an example. The advantage depends on the network being well connected and the evidence being consistent. (LLM, conf=0.87)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Moreover, the previous pairwise meta-analyses for individuals with MDD in the maintenance phase did not evaluate the risk of individual adverse events of antidepressants [7, 10, 11].”
§ Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis > Introduction
What the sources say
- Supportedcites [7] Kato M, Hori H, Inoue T, Iga J, Iwata M, Inagaki T, et al. Discontinuation of antidepressants after remission with antidepressant medication in major depressive disorder: a systematic review and meta-analysis. Mol Psychiatry. 2021;26:118–33. source
The Methods section identifies this as a pairwise meta-analysis of antidepressants versus placebo. Its stated outcomes are relapse, all-cause dropout, and dropout due to adverse events; it does not assess risks of individual adverse events. The cited paper therefore exemplifies the type of earlier analysis described in the claim. (LLM, conf=0.88)
- Supportedcites [10] Sim K, Lau WK, Sim J, Sum MY, Baldessarini RJ. Prevention of relapse and recurrence in adults with major depressive disorder: systematic review and meta-analyses of controlled trials. Int J Neuropsychopharmacol 2015;19:pyv076. source
The Methods > Data Extraction section (page unavailable) identifies relapse or recurrence rates and dropout rates as the extracted outcomes. Methods > Data Analysis (page unavailable) describes meta-analysis of treatment response, with no analysis of individual adverse-event risks. The claim accurately characterizes the scope of this review. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [11] Glue P, Donovan MR, Kolluri S, Emir B. Meta-analysis of relapse prevention antidepressant trials in depressive disorders. Aust N. Z J Psychiatry. 2010;44:697–705. source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“According to this meta-analysis, the antidepressant maintenance group had a significantly lower relapse rate than the antidepressant discontinuation group (odds ratio = 0.38, 95% confidence interval = 0.33–0.43, p < 0.00001).”
§ Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis > Introduction
What the sources say
- Supportedcites [7] Kato M, Hori H, Inoue T, Iga J, Iwata M, Inagaki T, et al. Discontinuation of antidepressants after remission with antidepressant medication in major depressive disorder: a systematic review and meta-analysis. Mol Psychiatry. 2021;26:118–33. source
The Results section (‘Relapse, acceptability, and tolerability at study endpoint’) reports a pooled relapse odds ratio of 0.38 (95% CI 0.33–0.43, p < 0.00001) across 40 studies, favoring antidepressant continuation over placebo. This matches the cited comparison between maintenance and discontinuation. (LLM, conf=0.95)
plainstates a causen = 8,890- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thus, no clear evidence of violations of the transitivity assumption for any of the potential effect modifiers analyzed was found (Table S5 and Appendix S1).”
§ Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis > Results > Efficacy
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The distribution of potential effect modifiers was similar across the comparisons in the network (Table S5).”
§ Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis > Results > Study characteristics
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
25 more claims
Create a free account to see all 67 claims and every source verdict.
- It may state two separate claims as one. 20
- Probably not a substantial claim. 23
- The quote only partly states this claim. 3
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552 · cited 1×
“Meta-analysis methods Both pairwise [14] and Bayesian network meta-analyses [15] were performed using the random-effects model [16].”
MethodHutton, B., Salanti, G., Caldwell, D. M., Chaimani, A., Schmid, C. H., Cameron, C., Ioannidis, J. P. A., Straus, S., Thorlund, K., Jansen, J. P., et al. (2015) · Annals of Internal Medicine · doi:10.7326/m14-2385 · Cited by 8,269 · cited 1×
“MATERIALS AND METHODS This study adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [12] (Table S1) and was registered on the Open Science Framework (https://osf.”
MethodCipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32802-7 · Cited by 3,541
CINeMA: an approach for assessing confidence in the results of a network meta-analysis
Nikolakopoulou, A., Higgins, J. P. T., Papakonstantinou, T., Chaimani, A., Del Giovane, C., Egger, M., & Salanti, G. (2020) · PLOS Medicine · doi:10.1371/journal.pmed.1003082 · Cited by 1,935
Evaluating the quality of evidence from a network meta-analysis
Salanti, G., Del Giovane, C., Chaimani, A., Caldwell, D. M., & Higgins, J. P. T. (2014) · PLoS ONE · doi:10.1371/journal.pone.0099682 · Cited by 1,402
Kennedy, S. H., Lam, R. W., McIntyre, R. S., Tourjman, S. V., Bhat, V., Blier, P., Hasnain, M., Jollant, F., Levitt, A. J., MacQueen, G. M., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716659417 · Cited by 1,181
Time for united action on depression: a Lancet–World Psychiatric Association Commission
Herrman, H., Patel, V., Kieling, C., Berk, M., Buchweitz, C., Cuijpers, P., Furukawa, T. A., Kessler, R. C., Kohrt, B. A., Maj, M., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02141-3 · Cited by 1,104 · cited 3×
“Therefore, maintenance therapy is necessary to avoid relapse/recurrence [1].”
BackgroundInfluentialConceptual and technical challenges in network meta-analysis
Cipriani, A., Higgins, J. P. T., Geddes, J. R., & Salanti, G. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-2-201307160-00008 · Cited by 1,072 · cited 1×
“We determined whether the distribution differences were large enough to threaten the validity of the analysis by comparing the distribution of these possible effect modifiers across treatments included in the network meta-analysis using the Kruskal–Wallis test (continuous variables), the Pearson chi-squared test or th…”
MethodAutomating network meta‐analysis
van Valkenhoef, G., Lu, G., de Brock, B., Hillege, H., Ades, A. E., & Welton, N. J. (2012) · Research Synthesis Methods · doi:10.1002/jrsm.1054 · Cited by 786 · cited 1×
“Meta-analysis methods Both pairwise [14] and Bayesian network meta-analyses [15] were performed using the random-effects model [16].”
MethodPapakonstantinou, T., Nikolakopoulou, A., Higgins, J. P. T., Egger, M., & Salanti, G. (2020) · Campbell Systematic Reviews · doi:10.1002/cl2.1080 · Cited by 596
Research works printed but not linked: 2
- Baldessarin IR Chemotherapy in Psychiatry, 3rd edition. Springer Press 2013; New York.
- Dekker J, Jonghe F, Tuynman H. The use of anti-depressants after recovery from depression. Eur J Psychiatry. 2000;14:207–12.
Cited by
Pillinger, T., Howes, O. D., Correll, C., Leucht, S., Huhn, M., Schneider-Thoma, J., Gaughran, F., Jauhar, S., McGuire, P., Taylor, D. M., et al. (2023) · Lancet psychiatry · doi:10.1016/s2215-0366(23)00262-6 · Cited by 133
“43 This outcome was due to the modest number of included drugs in the meta-analysis, and concerns regarding the validity of meta-analytic and ordinal regression models, thereby precluding imputation.”
BackgroundTheta burst stimulation for depression: a systematic review and network and pairwise meta-analysis
Kishi, T., Ikuta, T., Sakuma, K., Hatano, M., Matsuda, Y., Wilkening, J., Goya-Maldonado, R., Tik, M., Williams, N. R., Kito, S., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02630-5 · Cited by 74
Self-citationPolypharmacology: promises and new drugs in 2022
Ryszkiewicz, P., Malinowska, B., & Schlicker, E. (2023) · Pharmacological Reports · doi:10.1007/s43440-023-00501-4 · Cited by 76
Zheng, X., Qiu, J., Gao, N., Jiang, T., Li, Z., Zhang, W., Gong, Y., Hong, Z., & Hong, H. (2023) · Drug Design Development and Therapy · doi:10.2147/dddt.s417598 · Cited by 57
Chan, J. K. N., Solmi, M., Lo, H. K. Y., Chan, M. W. Y., Choo, L. L. T., Lai, E. T. H., Wong, C. S. M., Correll, C. U., & Chang, W. C. (2025) · World Psychiatry · doi:10.1002/wps.21354 · Cited by 65
Metadata
- Authors
- Kishi, T., Ikuta, T., Sakuma, K., Okuya, M., Hatano, M., Matsuda, Y., & Iwata, N.
- Affiliations
- Fujita Health University (JP)
- University of Mississippi (US)
- Jikei University School of Medicine (JP)
- Corresponding author
- Kishi, Taro
- Venue
- Molecular Psychiatry
- Published
- 2022-10-17
- Volume
- 28
- Issue
- 1
- Pages
- 402-409
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- PMC
- PMC9812779
- OpenAlex
- W4306404458
- Cited by
- 136
- References
- 56
- Citations by year
- 2026: 34 · 2025: 41 · 2024: 39 · 2023: 21 · 2022: 1
- FWCI
- 3.66
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Molecular Psychiatry (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Japan Agency for Medical Research and Development
- Kissei
- Eisai
- Shionogi
- Fujita Health University
- Kansai Medical University
- Japan Society for the Promotion of Science (21K15738)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Keywords
- antidepressants, major depressive disorder, maintenance therapy, relapse prevention, relapse rate, treatment discontinuation, adverse events, dizziness, nausea, venlafaxine, desvenlafaxine, paroxetine, vortioxetine, sertraline, agomelatine, mirtazapine, bupropion
- MeSH terms
- Duloxetine Hydrochloride, Desvenlafaxine Succinate, Venlafaxine Hydrochloride, Reboxetine, Vortioxetine, Mirtazapine, Adult, Amitriptyline, Antidepressive Agents, Major Depressive Disorder, Female, Fluoxetine, Humans, Thiazepines, Citalopram, Randomized Controlled Trials as Topic, Fluvoxamine, Paroxetine, Sertraline
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis. https://app.cochat.ai/papers/10.1038/s41380-022-01824-z
- The paper
- Kishi, T., Ikuta, T., Sakuma, K., Okuya, M., Hatano, M., Matsuda, Y., & Iwata, N. (2023). Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis. Molecular Psychiatry. https://doi.org/10.1038/s41380-022-01824-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.